Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

Inclusion Criteria: * Patients with either Hodgkin lymphoma or non-Hodgkin lymphoma * Patients with a previously harvested hematopoietic stem cells while in complete or partial remission, or in the case of patients with stable or refractory disease are undergoing autologous transplantation because it has been recommended by their treating physician as representing their best treatment option with a goal of at minimum of 2 x 10\^6 cluster of differentiation (CD)34+ peripheral primed stem cells per kilogram of actual body weight * Cardiac ejection fraction \>= 45% or clearance by Cleveland Clinic (CCF) physician * Diffusion capacity of the lung for carbon monoxide (DLCO) of \>= 45% predicted or clearance by CCF physician * Serum creatinine \< 2.0 mg/dl * Serum bilirubin \< 2.0 mg/dl * Females of childbearing potential must have a negative pregnancy test * Patients of childbearing potential must agree to use an effective birth control method * Patient must not have any other active malignancy (or malignancy must be in remission with no evidence of disease for the past 2 years) excluding nonmelanoma skin cancer * Patients must have had at least 17 days since their most recent cytoxic chemotherapy or radiation at the time of the initiation of their preparative regimen (day -9) * Serum glutamic oxaloacetic transaminase (SGOT) \< 2 times the normal or clearance by a CCF physician * Patients who are human immunodeficiency virus (HIV) positive: * Patients must be receiving concurr…